From a company press release : September 30, 2008 Media Contact: Greg Kelley, Feinstein Kean Healthcare (+++) +++-++++ Link Medicine Completes $40 million Series C Financing to Accelerate Development of First Disease-Modifying Treatments for Neurodegenerative Disorders Co-led by Clarus Ventures and SV Life Sciences,the Financing will Advance Preclinical and Clinical Programs CAMBRIDGE, Mass. - Link Medicine Corporation , a privately held biotechnology company advancing novel approaches for the treatment of neurodegenerative diseases, announced today that it has obtained $40 million of Series C equity financing to help move its lead preclinical programs into human clinical testing. The round was funded by two leading biotechnology investors - Clarus Ventures and SV Life Sciences. Link Medicine, founded in March 2005, is focused on developing the first disease-modifying therapies for the treatment of several neurodegenerative diseases - including Alzheimer's, Parkinson's, Hunting...
News about our knowledge of the brain and behavior
from Anthony Risser, Ph.D.